Skip to main content
Erschienen in: Journal of Neurology 7/2015

01.07.2015 | Original Communication

Thyroid hormone level is associated with motor symptoms in de novo Parkinson’s disease

verfasst von: Tadashi Umehara, Hiromasa Matsuno, Chizuko Toyoda, Hisayoshi Oka

Erschienen in: Journal of Neurology | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Sympathetic denervation has been observed not only in the myocardium but also in the thyroid of patients with Parkinson’s disease (PD). We investigated whether sympathetic denervation as indicated by decreased cardiac 123I-meta-iodobenzylguanidine uptake is associated with the levels of thyroid hormones and whether the levels of thyroid hormones affect clinical manifestations in patients with PD. The subjects were 75 patients with de novo PD and 20 age-matched healthy controls. We examined the levels of thyroid-stimulating hormone, free triiodothyronine, and free thyroxine, and evaluated the associations of these levels with cardiac 123I-meta-iodobenzylguanidine uptake and motor symptoms. The results showed that the free triiodothyronine level was below the normal range in 29 patients (approximately 40 %) and was significantly lower in the patients with PD than in the controls. The decreased free triiodothyronine level was associated with akinetic-rigid motor subtype and washout ratio of cardiac 123I-meta-iodobenzylguanidine scintigraphy. The free triiodothyronine level negatively correlated with disease severity. Thyroid-stimulating hormone level was within normal range. However, its level was lower in patients with tremor-dominant type or mixed type than in those with akinetic-rigid type. All correlations of these variables with the levels of thyroid hormones remained statistically significant on multiple regression analysis. Our results suggest that the thyroid hormone level, especially the free triiodothyronine level, is closely related to motor symptoms in patients with de novo PD. Further studies are needed to clarify whether the decreased hormone levels have functional roles in motor and non-motor symptoms.
Literatur
1.
Zurück zum Zitat Goldstein DS, Holmes CS, Dendi R, Bruce SR, Li ST (2002) Orthostatic hypotension from sympathetic denervation in Parkinson’s disease. Neurology 58:1247–1255CrossRefPubMed Goldstein DS, Holmes CS, Dendi R, Bruce SR, Li ST (2002) Orthostatic hypotension from sympathetic denervation in Parkinson’s disease. Neurology 58:1247–1255CrossRefPubMed
2.
Zurück zum Zitat Matsui H, Udaka F, Oda M et al (2005) Metaiodobenzylguanidine (MIBG) uptake in Parkinson’s disease also decreases at thyroid. Ann Nucl Med 19:225–229CrossRefPubMed Matsui H, Udaka F, Oda M et al (2005) Metaiodobenzylguanidine (MIBG) uptake in Parkinson’s disease also decreases at thyroid. Ann Nucl Med 19:225–229CrossRefPubMed
3.
Zurück zum Zitat Jang W, Kim JS, Cho JW, Ahn JY, Choi YY, Kim HT (2013) Thyroid MIBG uptake in Parkinson’s disease with diabetes mellitus. Clin Auton Res 23:221–224CrossRefPubMed Jang W, Kim JS, Cho JW, Ahn JY, Choi YY, Kim HT (2013) Thyroid MIBG uptake in Parkinson’s disease with diabetes mellitus. Clin Auton Res 23:221–224CrossRefPubMed
4.
Zurück zum Zitat Tipre DN, Goldstein DS (2005) Cardiac and extracardiac sympathetic denervation in Parkinson’s disease with orthostatic hypotension and in pure autonomic failure. J Nucl Med 46:1775–1781PubMed Tipre DN, Goldstein DS (2005) Cardiac and extracardiac sympathetic denervation in Parkinson’s disease with orthostatic hypotension and in pure autonomic failure. J Nucl Med 46:1775–1781PubMed
5.
Zurück zum Zitat Melander A, Ericson LE, Sundler F, Ingbar SH (1974) Sympathetic innervation of the mouse thyroid and its significance in thyroid hormone secretion. Endocrinology 94:959–966CrossRefPubMed Melander A, Ericson LE, Sundler F, Ingbar SH (1974) Sympathetic innervation of the mouse thyroid and its significance in thyroid hormone secretion. Endocrinology 94:959–966CrossRefPubMed
6.
Zurück zum Zitat Silva JE, Bianco SD (2008) Thyroid-adrenergic interactions: physiological and clinical implications. Thyroid 18:157–165CrossRefPubMed Silva JE, Bianco SD (2008) Thyroid-adrenergic interactions: physiological and clinical implications. Thyroid 18:157–165CrossRefPubMed
7.
Zurück zum Zitat Caradoc-Davies TH (1986) Resolution of dyskinesia and the “on–off” phenomenon in thyrotoxic patients with Parkinson’s disease after antithyroid treatment. Br Med J (Clin Res Ed) 293:38–39CrossRef Caradoc-Davies TH (1986) Resolution of dyskinesia and the “on–off” phenomenon in thyrotoxic patients with Parkinson’s disease after antithyroid treatment. Br Med J (Clin Res Ed) 293:38–39CrossRef
8.
Zurück zum Zitat Kim HT, Edwards MJ, Lakshmi Narsimhan R, Bhatia KP (2005) Hyperthyroidism exaggerating parkinsonian tremor: a clinical lesson. Parkinsonism Relat Disord 11:331–332CrossRefPubMed Kim HT, Edwards MJ, Lakshmi Narsimhan R, Bhatia KP (2005) Hyperthyroidism exaggerating parkinsonian tremor: a clinical lesson. Parkinsonism Relat Disord 11:331–332CrossRefPubMed
9.
Zurück zum Zitat Guerin V, Guyot C, Hartemann P (1990) Dysthyroidism and Parkinson’s disease. Ann Endocrinol (Paris) 51:43–45 Guerin V, Guyot C, Hartemann P (1990) Dysthyroidism and Parkinson’s disease. Ann Endocrinol (Paris) 51:43–45
10.
Zurück zum Zitat Prakash KM (2010) Hyperthyroidism “masked” the levodopa response in newly diagnosed Parkinson’s disease patients. Parkinsonism Relat Disord 16:691–692CrossRefPubMed Prakash KM (2010) Hyperthyroidism “masked” the levodopa response in newly diagnosed Parkinson’s disease patients. Parkinsonism Relat Disord 16:691–692CrossRefPubMed
11.
Zurück zum Zitat Flotats A, Carrio I, Agostini D, Le Guludec D, Marcassa C, Schafers M et al (2010) Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging 37:1802–1812CrossRefPubMed Flotats A, Carrio I, Agostini D, Le Guludec D, Marcassa C, Schafers M et al (2010) Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging 37:1802–1812CrossRefPubMed
12.
Zurück zum Zitat Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedCentralCrossRefPubMed Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedCentralCrossRefPubMed
13.
Zurück zum Zitat Spiegel J, Hellwig D, Samnick S et al (2007) Striatal FP-CIT uptake differs in the subtypes of early Parkinson’s disease. J Neural Transm 114:331–335CrossRefPubMed Spiegel J, Hellwig D, Samnick S et al (2007) Striatal FP-CIT uptake differs in the subtypes of early Parkinson’s disease. J Neural Transm 114:331–335CrossRefPubMed
14.
Zurück zum Zitat Sapin R, Schlienger JL (2003) Thyroxine (T4) and tri-iodothyronine (T3) determinations: techniques and value in the assessment of thyroid function. Ann Biol Clin (Paris) 61:411–420 Sapin R, Schlienger JL (2003) Thyroxine (T4) and tri-iodothyronine (T3) determinations: techniques and value in the assessment of thyroid function. Ann Biol Clin (Paris) 61:411–420
15.
Zurück zum Zitat Wingert TD, Hershman JM (1997) Sinemet and thyroid function in Parkinson’s disease. Neurology 29:1073–1074CrossRef Wingert TD, Hershman JM (1997) Sinemet and thyroid function in Parkinson’s disease. Neurology 29:1073–1074CrossRef
16.
Zurück zum Zitat Mannisto P, Mattila J, Kaakkola S (1981) Possible involvement of nigrostriatal dopamine system in the inhibition of thyrotropin secretion in the rat. Eur J Pharmacol 76:403–409CrossRefPubMed Mannisto P, Mattila J, Kaakkola S (1981) Possible involvement of nigrostriatal dopamine system in the inhibition of thyrotropin secretion in the rat. Eur J Pharmacol 76:403–409CrossRefPubMed
17.
Zurück zum Zitat Schilling JC, Adamus WS, Palluk R (1992) Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans. Clin Pharmacol Ther 51:541–548CrossRefPubMed Schilling JC, Adamus WS, Palluk R (1992) Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans. Clin Pharmacol Ther 51:541–548CrossRefPubMed
18.
19.
Zurück zum Zitat Munhoz RP, Teive HA, Troiano AR et al (2004) Parkinson’s disease and thyroid dysfunction. Parkinsonism Relat Disord 10:381–383CrossRefPubMed Munhoz RP, Teive HA, Troiano AR et al (2004) Parkinson’s disease and thyroid dysfunction. Parkinsonism Relat Disord 10:381–383CrossRefPubMed
20.
Zurück zum Zitat Bonuccelli U, D’Avino C, Caraccio N et al (1999) Thyroid function and autoimmunity in Parkinson’s disease: a study of 101 patients. Parkinsonsim Relat Disord 5:49–53CrossRef Bonuccelli U, D’Avino C, Caraccio N et al (1999) Thyroid function and autoimmunity in Parkinson’s disease: a study of 101 patients. Parkinsonsim Relat Disord 5:49–53CrossRef
21.
Zurück zum Zitat Tandeter H, Levy A, Gutman G, Shvartzman P (2001) Subclinical thyroid disease in patients with Parkinson’s disease. Arch Gerontol Geriatr 33:295–300CrossRefPubMed Tandeter H, Levy A, Gutman G, Shvartzman P (2001) Subclinical thyroid disease in patients with Parkinson’s disease. Arch Gerontol Geriatr 33:295–300CrossRefPubMed
22.
Zurück zum Zitat Falaschi P, Martocchia A, Proietti A et al (2004) The hypothalamic-pituitary-thyroid axis in subjects with subclinical thyroid diseases: the impact of the negative feedback mechanism. Neuro Endocrinol Lett 25:292–296PubMed Falaschi P, Martocchia A, Proietti A et al (2004) The hypothalamic-pituitary-thyroid axis in subjects with subclinical thyroid diseases: the impact of the negative feedback mechanism. Neuro Endocrinol Lett 25:292–296PubMed
23.
Zurück zum Zitat Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H (1999) (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease. J Neurol Neurosurgery Psychiatry 67(2):189–194CrossRef Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H (1999) (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease. J Neurol Neurosurgery Psychiatry 67(2):189–194CrossRef
24.
Zurück zum Zitat Oka H, Toyoda C, Yogo M, Mochio S (2011) Cardiovascular dysautonomia in de novo Parkinson’s disease without orthostatic hypotension. Eur J Neurol 18:286–292CrossRefPubMed Oka H, Toyoda C, Yogo M, Mochio S (2011) Cardiovascular dysautonomia in de novo Parkinson’s disease without orthostatic hypotension. Eur J Neurol 18:286–292CrossRefPubMed
25.
Zurück zum Zitat Orimo S, Uchihara T, Nakamura A et al (2008) Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson’s disease. Brain 131:642–650CrossRefPubMed Orimo S, Uchihara T, Nakamura A et al (2008) Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson’s disease. Brain 131:642–650CrossRefPubMed
26.
Zurück zum Zitat Cardinali DP, Vacas MI, Gejman PV (1981) The sympathetic superior cervical ganglia as peripheral neuroendocrine centers. J Neural Transm 52:1–21CrossRefPubMed Cardinali DP, Vacas MI, Gejman PV (1981) The sympathetic superior cervical ganglia as peripheral neuroendocrine centers. J Neural Transm 52:1–21CrossRefPubMed
27.
Zurück zum Zitat Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H (2010) Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease. Acta Neuropathol 119:703–713CrossRefPubMed Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H (2010) Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease. Acta Neuropathol 119:703–713CrossRefPubMed
28.
Zurück zum Zitat Imamura Y, Ando H, Ashihara T et al (1996) Myocardial adrenergic nervous activity is intensified in patients with heart failure without left ventricular volume or pressure overload. J Am Coll Cardiol 28:371–375CrossRefPubMed Imamura Y, Ando H, Ashihara T et al (1996) Myocardial adrenergic nervous activity is intensified in patients with heart failure without left ventricular volume or pressure overload. J Am Coll Cardiol 28:371–375CrossRefPubMed
29.
Zurück zum Zitat Sisson JC, Shapiro B, Meyers L et al (1987) Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 28:1625–1636PubMed Sisson JC, Shapiro B, Meyers L et al (1987) Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 28:1625–1636PubMed
30.
Zurück zum Zitat Tandeter HB, Shvartzman P (1993) Parkinson’s disease camouflaging early signs of hypothyroidism. Postgrad Med 94:187–190PubMed Tandeter HB, Shvartzman P (1993) Parkinson’s disease camouflaging early signs of hypothyroidism. Postgrad Med 94:187–190PubMed
31.
Zurück zum Zitat Garcia-Moreno JM, Chacon J (2002) Hypothyroidism concealed by Parkinson’s disease. Rev Neurol 35:741–742PubMed Garcia-Moreno JM, Chacon J (2002) Hypothyroidism concealed by Parkinson’s disease. Rev Neurol 35:741–742PubMed
32.
Zurück zum Zitat Garcia-Moreno JM, Chacon-Pena J (2003) Hypothyroidism and Parkinson’s disease and the issue of diagnostic confusion. Mov Disord 18:1058–1059CrossRefPubMed Garcia-Moreno JM, Chacon-Pena J (2003) Hypothyroidism and Parkinson’s disease and the issue of diagnostic confusion. Mov Disord 18:1058–1059CrossRefPubMed
33.
Zurück zum Zitat Samuels MH, Henry P, Ridqway EC (1992) Effects of dopamine and somatostatin on pulsatile pituitary glycoprotein secretion. J Clin Endocrinol Metab 74:217–222PubMed Samuels MH, Henry P, Ridqway EC (1992) Effects of dopamine and somatostatin on pulsatile pituitary glycoprotein secretion. J Clin Endocrinol Metab 74:217–222PubMed
34.
Zurück zum Zitat Rossi C, Frosini D, Volterrani D, De Feo P, Unti E, Nicoletti V et al (2010) Differences in nigro-striatal impairment in clinical variants of early Parkinson’s disease: evidence from a FP-CIT SPECT study. Eur J Neurol 17:626–630CrossRefPubMed Rossi C, Frosini D, Volterrani D, De Feo P, Unti E, Nicoletti V et al (2010) Differences in nigro-striatal impairment in clinical variants of early Parkinson’s disease: evidence from a FP-CIT SPECT study. Eur J Neurol 17:626–630CrossRefPubMed
Metadaten
Titel
Thyroid hormone level is associated with motor symptoms in de novo Parkinson’s disease
verfasst von
Tadashi Umehara
Hiromasa Matsuno
Chizuko Toyoda
Hisayoshi Oka
Publikationsdatum
01.07.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 7/2015
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-015-7780-x

Weitere Artikel der Ausgabe 7/2015

Journal of Neurology 7/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.